| Prior antiretroviral therapy experience protects against zidovudine-related anaemia. | |
| | |
MedLine Citation:
|
PMID: 17760739 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: We investigated the use of antiretroviral therapy regimens containing zidovudine or stavudine, using data from the TREAT Asia HIV Observational Database (TAHOD), a multicentre, prospective, observational study of an HIV-infected cohort in the Asia-Pacific Region. METHODS: A proportional hazards regression analysis of factors associated with the time to discontinuation of initial regimens containing zidovudine or stavudine and a logistic regression analysis to identify factors associated with a diagnosis of anaemia within 6 months of commencement of zidovudine in initial or subsequent regimens were performed. RESULTS: Patients who started zidovudine were more likely to stop within the first 9 months of treatment than those who started on stavudine; the reverse was true after 9 months. Anaemia (haemoglobin<or=10 g/dL) occurred in the first 6 months in 57 of 433 patients (13%) on zidovudine. Baseline anaemia was the strongest predictive factor for subsequent anaemia, and prior antiretroviral therapy (ART) experience was protective for development of anaemia. CONCLUSIONS: These data support baseline haemoglobin testing and avoidance of zidovudine if the patient is anaemic. The protective effect of prior ART for development of anaemia on zidovudine supports the short-term safety of a stavudine to zidovudine switch with routine haemoglobin monitoring in this cohort. Further studies in resource-poor settings of longer term efficacy and toxicities of ART switch strategies are needed. |
| | |
Authors:
|
S E Huffam; P Srasuebkul; J Zhou; A Calmy; V Saphonn; J M Kaldor; R Ditangco; |
Related Documents
:
|
15911439 - Spontaneous recovery of hemoglobin and neutrophil levels in japanese patients on a long... 1343089 - Three years' continuous low-dose interferon-alpha treatment of hairy-cell leukaemia: ev... 19616339 - Antiviral therapy reduces portal pressure in patients with cirrhosis due to hbeag-negat... 18537189 - Entecavir therapy for lamivudine-refractory chronic hepatitis b: improved virologic, bi... 10860129 - Long-term patient adherence to antiretroviral therapy. 17943989 - Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepati... 14740699 - Aortocoronary saphenous vein bypass graft changes 5 to 7 years after surgery. 19068259 - Three-year follow-up of a girl with chronic paroxysmal hemicrania. 11355029 - Quality-of-life assessment of morbidly obese patients who have undergone a lap-band ope... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: HIV medicine Volume: 8 ISSN: 1464-2662 ISO Abbreviation: HIV Med. Publication Date: 2007 Oct |
Date Detail:
|
Created Date: 2007-08-31 Completed Date: 2008-03-14 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897392 Medline TA: HIV Med Country: England |
Other Details:
|
Languages: eng Pagination: 465-71 Citation Subset: IM |
Affiliation:
|
National Center for HIV/AIDS, Dermatology and STDs (NCHADS), Ministry of Health, Phnom Penh, Cambodia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Acquired Immunodeficiency Syndrome
/
drug therapy* Adult Anemia / chemically induced, prevention & control* Anti-HIV Agents / adverse effects* Antiretroviral Therapy, Highly Active / methods* Asia Developing Countries Drug Therapy, Combination Female HIV / drug effects HIV Infections / drug therapy* Humans Male Middle Aged Multivariate Analysis Retrospective Studies Zidovudine / adverse effects* |
| Grant Support | |
ID/Acronym/Agency:
|
U01-AI069907/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 30516-87-1/Zidovudine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone a...
Next Document: Risk factors for death among patients in French Guiana: 1996-2005.